Compare KRMD & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRMD | STTK |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.8M | 275.9M |
| IPO Year | N/A | 2020 |
| Metric | KRMD | STTK |
|---|---|---|
| Price | $5.61 | $4.09 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $6.00 | $4.00 |
| AVG Volume (30 Days) | 143.9K | ★ 887.9K |
| Earning Date | 03-11-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $39,070,637.00 | $1,000,000.00 |
| Revenue This Year | $23.97 | N/A |
| Revenue Next Year | $18.20 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 22.12 | N/A |
| 52 Week Low | $1.86 | $0.69 |
| 52 Week High | $6.61 | $4.89 |
| Indicator | KRMD | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 49.03 | 52.66 |
| Support Level | $5.56 | $4.10 |
| Resistance Level | $5.85 | $4.65 |
| Average True Range (ATR) | 0.30 | 0.41 |
| MACD | -0.04 | -0.10 |
| Stochastic Oscillator | 59.04 | 17.82 |
KORU Medical Systems Inc is a developer and manufacturer of medical devices and supplies. It focuses on mechanical infusion products, the FREEDOM Infusion Systems. Its primary products include the Freedom Integrated Infusion System: the FREEDOM60 and FreedomEdge Syringe Drivers, Precision Flow Rate Tubing, HIgH-Flo Subcutaneous Safety Needle Sets and Precision Flow Rate Tubing. It is a manufacturer of subcutaneous infusion devices that deliver life-saving immunoglobulin therapies to patients with chronic illnesses such as Primary Immunodeficiencies (PIDD) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.